BeOne Medicines & Revolution Medicines Forge $6.8B Synergy: Asian Licensing Deal Creates Clinical & Commercial Win-Win
Two oncology powerhouses, BeOne Medicines AG (NASDAQ: ONC) and Revolution Medicines, Inc. (NASDAQ: RVMD), announced a landmark multi-part clinical collaboration and regional licensing agreement on August 10, 2026. The deal structures a textbook strategic synergy: BeOne acquires exclusive development and commercialization rights across select Asian markets (excluding Japan and South Korea) for Revolution’s four clinical-stage … Read more